激素最小化免疫抑制方案下新发肾移植受者矿物质代谢、骨转换与骨密度的自然史
本研究纳入69例成人新发肾移植受者,采用激素最小化免疫抑制方案,进行5年前瞻性观察。结果显示移植后骨转换活性下降,骨密度变化微小且仅在特定部位显著,骨密度变化与骨转换标志物相关而非累积糖皮质激素暴露。
要点
- 移植后骨转换活性整体下降,骨密度变化有限且变异大
- 骨密度变化与骨转换标志物相关,与累积激素暴露无关
- 激素最小化方案下骨丢失并不显著
核心结论
- 在激素最小化免疫抑制方案治疗的新发肾移植受者中,骨密度变化有限、高度变异,且与骨转换活性相关而非糖皮质激素暴露。
研究设计与样本
- 5年前瞻性观察研究,纳入69例成人新发肾移植受者(39例男性,年龄51.1±12.2岁),均未接受抗骨吸收治疗并采用激素最小化免疫抑制方案。
主要发现
- 移植后骨转换活性整体下降。
- 术后第一年超远端桡骨骨密度中位下降2.2%(IQR -5.9至1.2),P=0.01。
- 第1至5年腰椎骨密度中位增加1.6%(IQR -3.2至7.0),P=0.009。
- 骨转换标志物而非矿物质代谢参数或累积糖皮质激素暴露与骨密度变化相关。
- 骨密度变化与骨转换变化呈负相关。
关键数值与推荐
- 1年累积甲泼尼龙暴露量为2.5±0.8 g,5年为5.8±3.3 g。
临床怎么用
- 对于采用激素最小化方案的新发肾移植受者,骨密度变化有限,监测骨转换标志物可能有助于评估骨密度变化风险。
局限性
- 研究为观察性设计,样本量有限,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The skeletal effects of renal transplantation are not completely understood, especially in patients managed with a steroid minimization immunosuppressive protocol and long term. We enrolled 69 adult transplant recipients (39 males; ages 51.1 ± 12.2 years), free of antiresorptive therapy and managed with a steroid minimization immunosuppressive protocol, into a 5-year prospective observational study to evaluate changes in areal bone mineral density (aBMD), mineral metabolism and bone remodelling. Dual energy X-ray absorptiometry, laboratory parameters of mineral metabolism (including parathyroid hormone, sclerostin and fibroblast growth factor 23) and non-renal cleared bone turnover markers (BTMs) (bone-specific alkaline phosphatase, trimeric N-terminal propeptide and tartrate-resistant acid phosphatase 5b) were assessed at baseline and 1 and 5 years post-transplantation. The mean cumulative methylprednisolone exposure at 1 and 5 years amounted to 2.5 ± 0.8 and 5.8 ± 3.3 g, respectively. Overall, bone remodelling activity decreased after transplantation. Post-transplant aBMD changes were minimal and were significant only in the ultradistal radius during the first post-operative year {median -2.2% [interquartile range (IQR) -5.9-1.2] decline, P = 0.01} and in the lumbar spine between Years 1 and 5 [median 1.6% (IQR -3.2-7.0) increase, P = 0.009]. BTMs, as opposed to mineral metabolism parameters and cumulative corticosteroid exposure, associated with aBMD changes, both in the early and late post-transplant period. Most notably, aBMD changes inversely associated with bone remodelling changes. In summary, in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol, BMD changes are limited, highly variable and related to remodelling activity rather than corticosteroid exposure.
引用
- Evenepoel P, Claes K, Meijers B, et al. Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrol Dial Transplant. 2020. PMID: 30339234. doi:10.1093/ndt/gfy306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。